Review



gsk3 kinase inhibitor chir99021  (BPS Bioscience)


Bioz Manufacturer Symbol BPS Bioscience manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    BPS Bioscience gsk3 kinase inhibitor chir99021
    A Scheme of phosphosite prediction pipeline using βIV spectrin sequence and eukaryotic linear motif phosphosite predictor. B Predicted peptide sequence logos for <t>GSK3</t> (left) and AKT (right). Amino acids are colored based on their chemical composition. Red - acidic, blue - basic, black - hydrophobic, purple – neutral, and green - polar. C βIV spectrin sequences predicted to be phosphorylated by either GSK3 or AKT. D Additional in silico prediction of phosphosites using the Phosphosite Plus Kinase Library showing likelihood of phosphorylation by GSK (blue) or AKT (green). Darker color indicates greater likelihood of phosphorylation of specific residues by GKS3 or AKT (ranked 1–100, 1 = highest likelihood). Gray squares indicate no phosphorylation sites at specific residues E . Matching key for ranked sites in D .
    Gsk3 Kinase Inhibitor Chir99021, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gsk3 kinase inhibitor chir99021/product/BPS Bioscience
    Average 94 stars, based on 5 article reviews
    gsk3 kinase inhibitor chir99021 - by Bioz Stars, 2026-03
    94/100 stars

    Images

    1) Product Images from "βIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia"

    Article Title: βIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia

    Journal: Molecular Psychiatry

    doi: 10.1038/s41380-025-02917-1

    A Scheme of phosphosite prediction pipeline using βIV spectrin sequence and eukaryotic linear motif phosphosite predictor. B Predicted peptide sequence logos for GSK3 (left) and AKT (right). Amino acids are colored based on their chemical composition. Red - acidic, blue - basic, black - hydrophobic, purple – neutral, and green - polar. C βIV spectrin sequences predicted to be phosphorylated by either GSK3 or AKT. D Additional in silico prediction of phosphosites using the Phosphosite Plus Kinase Library showing likelihood of phosphorylation by GSK (blue) or AKT (green). Darker color indicates greater likelihood of phosphorylation of specific residues by GKS3 or AKT (ranked 1–100, 1 = highest likelihood). Gray squares indicate no phosphorylation sites at specific residues E . Matching key for ranked sites in D .
    Figure Legend Snippet: A Scheme of phosphosite prediction pipeline using βIV spectrin sequence and eukaryotic linear motif phosphosite predictor. B Predicted peptide sequence logos for GSK3 (left) and AKT (right). Amino acids are colored based on their chemical composition. Red - acidic, blue - basic, black - hydrophobic, purple – neutral, and green - polar. C βIV spectrin sequences predicted to be phosphorylated by either GSK3 or AKT. D Additional in silico prediction of phosphosites using the Phosphosite Plus Kinase Library showing likelihood of phosphorylation by GSK (blue) or AKT (green). Darker color indicates greater likelihood of phosphorylation of specific residues by GKS3 or AKT (ranked 1–100, 1 = highest likelihood). Gray squares indicate no phosphorylation sites at specific residues E . Matching key for ranked sites in D .

    Techniques Used: Phospho-proteomics, Sequencing, In Silico

    A Full sequence of βIV spectrin and predicted phosphosite locations. Predicted GSK3 phosphosites (S45, T352, S2543 and T2541) are shown in yellow. The predicted AKT phosphosite (S119) is shown in orange. B Predicted phosphosite residues within AlphaFold structure of βIV spectrin are depicted at S119 (top), S45 (right), T352 (bottom), S2543 and T2541 (left). C Sequence of peptides used for in vitro phosphorylation. D Real-time luminescence from the Kinase-Glo reaction showing GSK3β activity in presence of control peptide (gray), βIV spectrin peptide containing S45 (teal) and βIV spectrin containing S2543 (green) in the presence of vehicle (darker colors) and CHIR99021 (lighter colors), with corresponding summary bar graphs (n = 3 reactions per tested condition). **p < 0.01 t-test. Each dot represents an independent reaction, each with 6 technical replicates.
    Figure Legend Snippet: A Full sequence of βIV spectrin and predicted phosphosite locations. Predicted GSK3 phosphosites (S45, T352, S2543 and T2541) are shown in yellow. The predicted AKT phosphosite (S119) is shown in orange. B Predicted phosphosite residues within AlphaFold structure of βIV spectrin are depicted at S119 (top), S45 (right), T352 (bottom), S2543 and T2541 (left). C Sequence of peptides used for in vitro phosphorylation. D Real-time luminescence from the Kinase-Glo reaction showing GSK3β activity in presence of control peptide (gray), βIV spectrin peptide containing S45 (teal) and βIV spectrin containing S2543 (green) in the presence of vehicle (darker colors) and CHIR99021 (lighter colors), with corresponding summary bar graphs (n = 3 reactions per tested condition). **p < 0.01 t-test. Each dot represents an independent reaction, each with 6 technical replicates.

    Techniques Used: Sequencing, Phospho-proteomics, In Vitro, Activity Assay, Control

    A Staining of MAP2, βIV spectrin, and AIS marker (neurofascin) in neurons derived from HC iPSCs treated with vehicle (DMSO), GSK3 inhibitor (20 μM CHIR99021), or AKT inhibitor (50 μM triciribine). B Staining of MAP2, βIV spectrin, and AIS marker in neurons derived from SCZ iPSCs. Scale bar in ( Bx ) indicates 20 μm. C Effect of kinase inhibition on βIV spectrin intensity at the AIS (n = 66 HC DMSO, 93 SCZ DMSO, 72 HC GSK3 inh., 68 SCZ GSK3 inh., 76 HC AKT inh., 64 SCZ AKT inh.), soma (n = 70 HC DMSO, 136 SCZ DMSO, 91 HC GSK3 inh., 109 SCZ GSK3 inh., 72 HC AKT inh., 128 SCZ AKT inh.), AIS:soma ratio (n = 36 HC DMSO, 65 SCZ DMSO, 39 HC GSK3 inh., 52 SCZ GSK3 inh., 44 HC AKT inh., 49 SCZ AKT inh.), and length of staining at the AIS. # p < 0.05 and ## p < 0.01 by two-way mixed model ANOVA with Dunnett’s multiple comparisons test (within group effect of inhibitor vs. DMSO). *p < 0.05 and **p < 0.01 following two-way mixed model ANOVA with Sidak’s multiple comparisons test (between-groups comparison of inhibitor treatment). All data are from n = 2 HC cell lines and n = 3 SCZ cell lines. Each dot represents an individual cell measurement.
    Figure Legend Snippet: A Staining of MAP2, βIV spectrin, and AIS marker (neurofascin) in neurons derived from HC iPSCs treated with vehicle (DMSO), GSK3 inhibitor (20 μM CHIR99021), or AKT inhibitor (50 μM triciribine). B Staining of MAP2, βIV spectrin, and AIS marker in neurons derived from SCZ iPSCs. Scale bar in ( Bx ) indicates 20 μm. C Effect of kinase inhibition on βIV spectrin intensity at the AIS (n = 66 HC DMSO, 93 SCZ DMSO, 72 HC GSK3 inh., 68 SCZ GSK3 inh., 76 HC AKT inh., 64 SCZ AKT inh.), soma (n = 70 HC DMSO, 136 SCZ DMSO, 91 HC GSK3 inh., 109 SCZ GSK3 inh., 72 HC AKT inh., 128 SCZ AKT inh.), AIS:soma ratio (n = 36 HC DMSO, 65 SCZ DMSO, 39 HC GSK3 inh., 52 SCZ GSK3 inh., 44 HC AKT inh., 49 SCZ AKT inh.), and length of staining at the AIS. # p < 0.05 and ## p < 0.01 by two-way mixed model ANOVA with Dunnett’s multiple comparisons test (within group effect of inhibitor vs. DMSO). *p < 0.05 and **p < 0.01 following two-way mixed model ANOVA with Sidak’s multiple comparisons test (between-groups comparison of inhibitor treatment). All data are from n = 2 HC cell lines and n = 3 SCZ cell lines. Each dot represents an individual cell measurement.

    Techniques Used: Staining, Marker, Derivative Assay, Inhibition, Comparison

    A Zoom to AIS of HC and SCZ neurons treated with vehicle, GSK3 or AKT inhibitor showing MAP2 (blue) and accumulation of βIV spectrin (red) at the AIS. White arrows indicate beginning and end of AIS ROI and the scale bar is 2 μm. B AIS fluorescence intensity signal of βIV spectrin. C Classification accuracy based on sorting signals between HC and SCZ groups for DMSO, GSK3 inhibitor, and AKT inhibitor-treated neurons. D Classification accuracy based on sorting signals between DMSO and GSK3 inhibitor-treated cells for HC and SCZ neurons, respectively. E Classification accuracy based on sorting signals between DMSO and AKT inhibitor-treated cells for HC and SCZ neurons, respectively. F Table of classification accuracy of all groups. The highest sorting accuracy was from SCZ neurons treated with AKT inhibitor.
    Figure Legend Snippet: A Zoom to AIS of HC and SCZ neurons treated with vehicle, GSK3 or AKT inhibitor showing MAP2 (blue) and accumulation of βIV spectrin (red) at the AIS. White arrows indicate beginning and end of AIS ROI and the scale bar is 2 μm. B AIS fluorescence intensity signal of βIV spectrin. C Classification accuracy based on sorting signals between HC and SCZ groups for DMSO, GSK3 inhibitor, and AKT inhibitor-treated neurons. D Classification accuracy based on sorting signals between DMSO and GSK3 inhibitor-treated cells for HC and SCZ neurons, respectively. E Classification accuracy based on sorting signals between DMSO and AKT inhibitor-treated cells for HC and SCZ neurons, respectively. F Table of classification accuracy of all groups. The highest sorting accuracy was from SCZ neurons treated with AKT inhibitor.

    Techniques Used: Fluorescence

    A Staining of MAP2 and βIV spectrin in neurons derived from HC iPSCs treated with vehicle (DMSO), GSK3 inhibitor (20 μM CHIR99021) or AKT inhibitor (50 μM triciribine). Scale bar in Ax is 20 μm. B Staining of MAP2 and βIV spectrin in neurons derived from SCZ patients with a 16p11.2 microduplication. Scale bar in Bx is 20 μm. C Effect of kinase inhibition on βIV spectrin fluorescence in neurites (n = 43 HC DMSO, 31 SCZ DMSO, 61 HC GSK3 inh., 23 SCZ GSK3 inh., 56 HC AKT inh., 24 SCZ AKT inh.). D Zoom to neurites of HC and SCZ neurons treated with vehicle, GSK3 or AKT inhibitor stained with MAP2 (blue) and accumulation of βIV spectrin (red) at the AIS. White arrows indicate beginning and end of neurite ROI and the scale bar is 5 μm. E Fluorescence intensity signal of βIV spectrin in neurites. F Classification accuracy based on sorting signals between HC and SCZ groups for DMSO, GSK3 inhibitor and AKT inhibitor-treated neurons. G Classification accuracy based on sorting signals between DMSO and GSK3 inhibitor-treated cells for HC and SCZ neurons, respectively. H Classification accuracy based on sorting signals between DMSO and AKT inhibitor-treated cells for HC and SCZ neurons, respectively. I Table of classification accuracy of all groups. # p < 0.05 by two-way mixed model ANOVA with Dunnett’s multiple comparisons test (within group effect of inhibitor vs. DMSO). *p < 0.05 and following two-way mixed model ANOVA with Sidak’s multiple comparisons test (between groups comparison of inhibitor treatment). All data are from n = 2 HC cell lines and n = 2 SCZ cell lines from patients with 16p11.2 microduplication. Each dot represents an individual cell measurement.
    Figure Legend Snippet: A Staining of MAP2 and βIV spectrin in neurons derived from HC iPSCs treated with vehicle (DMSO), GSK3 inhibitor (20 μM CHIR99021) or AKT inhibitor (50 μM triciribine). Scale bar in Ax is 20 μm. B Staining of MAP2 and βIV spectrin in neurons derived from SCZ patients with a 16p11.2 microduplication. Scale bar in Bx is 20 μm. C Effect of kinase inhibition on βIV spectrin fluorescence in neurites (n = 43 HC DMSO, 31 SCZ DMSO, 61 HC GSK3 inh., 23 SCZ GSK3 inh., 56 HC AKT inh., 24 SCZ AKT inh.). D Zoom to neurites of HC and SCZ neurons treated with vehicle, GSK3 or AKT inhibitor stained with MAP2 (blue) and accumulation of βIV spectrin (red) at the AIS. White arrows indicate beginning and end of neurite ROI and the scale bar is 5 μm. E Fluorescence intensity signal of βIV spectrin in neurites. F Classification accuracy based on sorting signals between HC and SCZ groups for DMSO, GSK3 inhibitor and AKT inhibitor-treated neurons. G Classification accuracy based on sorting signals between DMSO and GSK3 inhibitor-treated cells for HC and SCZ neurons, respectively. H Classification accuracy based on sorting signals between DMSO and AKT inhibitor-treated cells for HC and SCZ neurons, respectively. I Table of classification accuracy of all groups. # p < 0.05 by two-way mixed model ANOVA with Dunnett’s multiple comparisons test (within group effect of inhibitor vs. DMSO). *p < 0.05 and following two-way mixed model ANOVA with Sidak’s multiple comparisons test (between groups comparison of inhibitor treatment). All data are from n = 2 HC cell lines and n = 2 SCZ cell lines from patients with 16p11.2 microduplication. Each dot represents an individual cell measurement.

    Techniques Used: Staining, Derivative Assay, Inhibition, Fluorescence, Comparison



    Similar Products

    glycogen synthase kinase 3 gsk3 inhibitor chir99021  (Tocris)
    93
    Tocris glycogen synthase kinase 3 gsk3 inhibitor chir99021
    Glycogen Synthase Kinase 3 Gsk3 Inhibitor Chir99021, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glycogen synthase kinase 3 gsk3 inhibitor chir99021/product/Tocris
    Average 93 stars, based on 1 article reviews
    glycogen synthase kinase 3 gsk3 inhibitor chir99021 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    gsk3 kinase inhibitor chir99021  (BPS Bioscience)
    94
    BPS Bioscience gsk3 kinase inhibitor chir99021
    A Scheme of phosphosite prediction pipeline using βIV spectrin sequence and eukaryotic linear motif phosphosite predictor. B Predicted peptide sequence logos for <t>GSK3</t> (left) and AKT (right). Amino acids are colored based on their chemical composition. Red - acidic, blue - basic, black - hydrophobic, purple – neutral, and green - polar. C βIV spectrin sequences predicted to be phosphorylated by either GSK3 or AKT. D Additional in silico prediction of phosphosites using the Phosphosite Plus Kinase Library showing likelihood of phosphorylation by GSK (blue) or AKT (green). Darker color indicates greater likelihood of phosphorylation of specific residues by GKS3 or AKT (ranked 1–100, 1 = highest likelihood). Gray squares indicate no phosphorylation sites at specific residues E . Matching key for ranked sites in D .
    Gsk3 Kinase Inhibitor Chir99021, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gsk3 kinase inhibitor chir99021/product/BPS Bioscience
    Average 94 stars, based on 1 article reviews
    gsk3 kinase inhibitor chir99021 - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    glycogen synthase kinase 3 gsk3 inhibitor chir99021  (Biogems International)
    95
    Biogems International glycogen synthase kinase 3 gsk3 inhibitor chir99021
    A Scheme of phosphosite prediction pipeline using βIV spectrin sequence and eukaryotic linear motif phosphosite predictor. B Predicted peptide sequence logos for <t>GSK3</t> (left) and AKT (right). Amino acids are colored based on their chemical composition. Red - acidic, blue - basic, black - hydrophobic, purple – neutral, and green - polar. C βIV spectrin sequences predicted to be phosphorylated by either GSK3 or AKT. D Additional in silico prediction of phosphosites using the Phosphosite Plus Kinase Library showing likelihood of phosphorylation by GSK (blue) or AKT (green). Darker color indicates greater likelihood of phosphorylation of specific residues by GKS3 or AKT (ranked 1–100, 1 = highest likelihood). Gray squares indicate no phosphorylation sites at specific residues E . Matching key for ranked sites in D .
    Glycogen Synthase Kinase 3 Gsk3 Inhibitor Chir99021, supplied by Biogems International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glycogen synthase kinase 3 gsk3 inhibitor chir99021/product/Biogems International
    Average 95 stars, based on 1 article reviews
    glycogen synthase kinase 3 gsk3 inhibitor chir99021 - by Bioz Stars, 2026-03
    95/100 stars
    		  Buy from Supplier
    glycogen synthase kinase 3 (gsk3) inhibitor chir99021 (chir)  (Millipore)
    90
    Millipore glycogen synthase kinase 3 (gsk3) inhibitor chir99021 (chir)
    A Scheme of phosphosite prediction pipeline using βIV spectrin sequence and eukaryotic linear motif phosphosite predictor. B Predicted peptide sequence logos for <t>GSK3</t> (left) and AKT (right). Amino acids are colored based on their chemical composition. Red - acidic, blue - basic, black - hydrophobic, purple – neutral, and green - polar. C βIV spectrin sequences predicted to be phosphorylated by either GSK3 or AKT. D Additional in silico prediction of phosphosites using the Phosphosite Plus Kinase Library showing likelihood of phosphorylation by GSK (blue) or AKT (green). Darker color indicates greater likelihood of phosphorylation of specific residues by GKS3 or AKT (ranked 1–100, 1 = highest likelihood). Gray squares indicate no phosphorylation sites at specific residues E . Matching key for ranked sites in D .
    Glycogen Synthase Kinase 3 (Gsk3) Inhibitor Chir99021 (Chir), supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/glycogen synthase kinase 3 (gsk3) inhibitor chir99021 (chir)/product/Millipore
    Average 90 stars, based on 1 article reviews
    glycogen synthase kinase 3 (gsk3) inhibitor chir99021 (chir) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    chir99021 (inhibitor of gsk3 kinase)  (Millipore)
    90
    Millipore chir99021 (inhibitor of gsk3 kinase)
    A Scheme of phosphosite prediction pipeline using βIV spectrin sequence and eukaryotic linear motif phosphosite predictor. B Predicted peptide sequence logos for <t>GSK3</t> (left) and AKT (right). Amino acids are colored based on their chemical composition. Red - acidic, blue - basic, black - hydrophobic, purple – neutral, and green - polar. C βIV spectrin sequences predicted to be phosphorylated by either GSK3 or AKT. D Additional in silico prediction of phosphosites using the Phosphosite Plus Kinase Library showing likelihood of phosphorylation by GSK (blue) or AKT (green). Darker color indicates greater likelihood of phosphorylation of specific residues by GKS3 or AKT (ranked 1–100, 1 = highest likelihood). Gray squares indicate no phosphorylation sites at specific residues E . Matching key for ranked sites in D .
    Chir99021 (Inhibitor Of Gsk3 Kinase), supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/chir99021 (inhibitor of gsk3 kinase)/product/Millipore
    Average 90 stars, based on 1 article reviews
    chir99021 (inhibitor of gsk3 kinase) - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    3 μm glycogen synthase kinase 3 (gsk3) inhibitor chir99021  (Axon Medchem LLC)
    90
    Axon Medchem LLC 3 μm glycogen synthase kinase 3 (gsk3) inhibitor chir99021
    A Scheme of phosphosite prediction pipeline using βIV spectrin sequence and eukaryotic linear motif phosphosite predictor. B Predicted peptide sequence logos for <t>GSK3</t> (left) and AKT (right). Amino acids are colored based on their chemical composition. Red - acidic, blue - basic, black - hydrophobic, purple – neutral, and green - polar. C βIV spectrin sequences predicted to be phosphorylated by either GSK3 or AKT. D Additional in silico prediction of phosphosites using the Phosphosite Plus Kinase Library showing likelihood of phosphorylation by GSK (blue) or AKT (green). Darker color indicates greater likelihood of phosphorylation of specific residues by GKS3 or AKT (ranked 1–100, 1 = highest likelihood). Gray squares indicate no phosphorylation sites at specific residues E . Matching key for ranked sites in D .
    3 μm Glycogen Synthase Kinase 3 (Gsk3) Inhibitor Chir99021, supplied by Axon Medchem LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/3 μm glycogen synthase kinase 3 (gsk3) inhibitor chir99021/product/Axon Medchem LLC
    Average 90 stars, based on 1 article reviews
    3 μm glycogen synthase kinase 3 (gsk3) inhibitor chir99021 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    A Scheme of phosphosite prediction pipeline using βIV spectrin sequence and eukaryotic linear motif phosphosite predictor. B Predicted peptide sequence logos for GSK3 (left) and AKT (right). Amino acids are colored based on their chemical composition. Red - acidic, blue - basic, black - hydrophobic, purple – neutral, and green - polar. C βIV spectrin sequences predicted to be phosphorylated by either GSK3 or AKT. D Additional in silico prediction of phosphosites using the Phosphosite Plus Kinase Library showing likelihood of phosphorylation by GSK (blue) or AKT (green). Darker color indicates greater likelihood of phosphorylation of specific residues by GKS3 or AKT (ranked 1–100, 1 = highest likelihood). Gray squares indicate no phosphorylation sites at specific residues E . Matching key for ranked sites in D .

    Journal: Molecular Psychiatry

    Article Title: βIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia

    doi: 10.1038/s41380-025-02917-1

    Figure Lengend Snippet: A Scheme of phosphosite prediction pipeline using βIV spectrin sequence and eukaryotic linear motif phosphosite predictor. B Predicted peptide sequence logos for GSK3 (left) and AKT (right). Amino acids are colored based on their chemical composition. Red - acidic, blue - basic, black - hydrophobic, purple – neutral, and green - polar. C βIV spectrin sequences predicted to be phosphorylated by either GSK3 or AKT. D Additional in silico prediction of phosphosites using the Phosphosite Plus Kinase Library showing likelihood of phosphorylation by GSK (blue) or AKT (green). Darker color indicates greater likelihood of phosphorylation of specific residues by GKS3 or AKT (ranked 1–100, 1 = highest likelihood). Gray squares indicate no phosphorylation sites at specific residues E . Matching key for ranked sites in D .

    Article Snippet: The phosphorylation activity of β-IV spectrin peptides (PEP S-45: PAASTAAASLFECSRIK, PEP S-2543: RWGQTLPTTSSTDEGNPKR) and GSK3 peptide (H-YRRAAVPPSPSLSRHSSPHQ-pSer-EDEEE-NH2, positive control) against GSK3 kinase inhibitor CHIR99021 was evaluated using a GSK3β kinase activity assay kit (BPS Bioscience, San Diego, CA) according to the manufacturer’s protocol.

    Techniques: Phospho-proteomics, Sequencing, In Silico

    A Full sequence of βIV spectrin and predicted phosphosite locations. Predicted GSK3 phosphosites (S45, T352, S2543 and T2541) are shown in yellow. The predicted AKT phosphosite (S119) is shown in orange. B Predicted phosphosite residues within AlphaFold structure of βIV spectrin are depicted at S119 (top), S45 (right), T352 (bottom), S2543 and T2541 (left). C Sequence of peptides used for in vitro phosphorylation. D Real-time luminescence from the Kinase-Glo reaction showing GSK3β activity in presence of control peptide (gray), βIV spectrin peptide containing S45 (teal) and βIV spectrin containing S2543 (green) in the presence of vehicle (darker colors) and CHIR99021 (lighter colors), with corresponding summary bar graphs (n = 3 reactions per tested condition). **p < 0.01 t-test. Each dot represents an independent reaction, each with 6 technical replicates.

    Journal: Molecular Psychiatry

    Article Title: βIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia

    doi: 10.1038/s41380-025-02917-1

    Figure Lengend Snippet: A Full sequence of βIV spectrin and predicted phosphosite locations. Predicted GSK3 phosphosites (S45, T352, S2543 and T2541) are shown in yellow. The predicted AKT phosphosite (S119) is shown in orange. B Predicted phosphosite residues within AlphaFold structure of βIV spectrin are depicted at S119 (top), S45 (right), T352 (bottom), S2543 and T2541 (left). C Sequence of peptides used for in vitro phosphorylation. D Real-time luminescence from the Kinase-Glo reaction showing GSK3β activity in presence of control peptide (gray), βIV spectrin peptide containing S45 (teal) and βIV spectrin containing S2543 (green) in the presence of vehicle (darker colors) and CHIR99021 (lighter colors), with corresponding summary bar graphs (n = 3 reactions per tested condition). **p < 0.01 t-test. Each dot represents an independent reaction, each with 6 technical replicates.

    Article Snippet: The phosphorylation activity of β-IV spectrin peptides (PEP S-45: PAASTAAASLFECSRIK, PEP S-2543: RWGQTLPTTSSTDEGNPKR) and GSK3 peptide (H-YRRAAVPPSPSLSRHSSPHQ-pSer-EDEEE-NH2, positive control) against GSK3 kinase inhibitor CHIR99021 was evaluated using a GSK3β kinase activity assay kit (BPS Bioscience, San Diego, CA) according to the manufacturer’s protocol.

    Techniques: Sequencing, Phospho-proteomics, In Vitro, Activity Assay, Control

    A Staining of MAP2, βIV spectrin, and AIS marker (neurofascin) in neurons derived from HC iPSCs treated with vehicle (DMSO), GSK3 inhibitor (20 μM CHIR99021), or AKT inhibitor (50 μM triciribine). B Staining of MAP2, βIV spectrin, and AIS marker in neurons derived from SCZ iPSCs. Scale bar in ( Bx ) indicates 20 μm. C Effect of kinase inhibition on βIV spectrin intensity at the AIS (n = 66 HC DMSO, 93 SCZ DMSO, 72 HC GSK3 inh., 68 SCZ GSK3 inh., 76 HC AKT inh., 64 SCZ AKT inh.), soma (n = 70 HC DMSO, 136 SCZ DMSO, 91 HC GSK3 inh., 109 SCZ GSK3 inh., 72 HC AKT inh., 128 SCZ AKT inh.), AIS:soma ratio (n = 36 HC DMSO, 65 SCZ DMSO, 39 HC GSK3 inh., 52 SCZ GSK3 inh., 44 HC AKT inh., 49 SCZ AKT inh.), and length of staining at the AIS. # p < 0.05 and ## p < 0.01 by two-way mixed model ANOVA with Dunnett’s multiple comparisons test (within group effect of inhibitor vs. DMSO). *p < 0.05 and **p < 0.01 following two-way mixed model ANOVA with Sidak’s multiple comparisons test (between-groups comparison of inhibitor treatment). All data are from n = 2 HC cell lines and n = 3 SCZ cell lines. Each dot represents an individual cell measurement.

    Journal: Molecular Psychiatry

    Article Title: βIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia

    doi: 10.1038/s41380-025-02917-1

    Figure Lengend Snippet: A Staining of MAP2, βIV spectrin, and AIS marker (neurofascin) in neurons derived from HC iPSCs treated with vehicle (DMSO), GSK3 inhibitor (20 μM CHIR99021), or AKT inhibitor (50 μM triciribine). B Staining of MAP2, βIV spectrin, and AIS marker in neurons derived from SCZ iPSCs. Scale bar in ( Bx ) indicates 20 μm. C Effect of kinase inhibition on βIV spectrin intensity at the AIS (n = 66 HC DMSO, 93 SCZ DMSO, 72 HC GSK3 inh., 68 SCZ GSK3 inh., 76 HC AKT inh., 64 SCZ AKT inh.), soma (n = 70 HC DMSO, 136 SCZ DMSO, 91 HC GSK3 inh., 109 SCZ GSK3 inh., 72 HC AKT inh., 128 SCZ AKT inh.), AIS:soma ratio (n = 36 HC DMSO, 65 SCZ DMSO, 39 HC GSK3 inh., 52 SCZ GSK3 inh., 44 HC AKT inh., 49 SCZ AKT inh.), and length of staining at the AIS. # p < 0.05 and ## p < 0.01 by two-way mixed model ANOVA with Dunnett’s multiple comparisons test (within group effect of inhibitor vs. DMSO). *p < 0.05 and **p < 0.01 following two-way mixed model ANOVA with Sidak’s multiple comparisons test (between-groups comparison of inhibitor treatment). All data are from n = 2 HC cell lines and n = 3 SCZ cell lines. Each dot represents an individual cell measurement.

    Article Snippet: The phosphorylation activity of β-IV spectrin peptides (PEP S-45: PAASTAAASLFECSRIK, PEP S-2543: RWGQTLPTTSSTDEGNPKR) and GSK3 peptide (H-YRRAAVPPSPSLSRHSSPHQ-pSer-EDEEE-NH2, positive control) against GSK3 kinase inhibitor CHIR99021 was evaluated using a GSK3β kinase activity assay kit (BPS Bioscience, San Diego, CA) according to the manufacturer’s protocol.

    Techniques: Staining, Marker, Derivative Assay, Inhibition, Comparison

    A Zoom to AIS of HC and SCZ neurons treated with vehicle, GSK3 or AKT inhibitor showing MAP2 (blue) and accumulation of βIV spectrin (red) at the AIS. White arrows indicate beginning and end of AIS ROI and the scale bar is 2 μm. B AIS fluorescence intensity signal of βIV spectrin. C Classification accuracy based on sorting signals between HC and SCZ groups for DMSO, GSK3 inhibitor, and AKT inhibitor-treated neurons. D Classification accuracy based on sorting signals between DMSO and GSK3 inhibitor-treated cells for HC and SCZ neurons, respectively. E Classification accuracy based on sorting signals between DMSO and AKT inhibitor-treated cells for HC and SCZ neurons, respectively. F Table of classification accuracy of all groups. The highest sorting accuracy was from SCZ neurons treated with AKT inhibitor.

    Journal: Molecular Psychiatry

    Article Title: βIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia

    doi: 10.1038/s41380-025-02917-1

    Figure Lengend Snippet: A Zoom to AIS of HC and SCZ neurons treated with vehicle, GSK3 or AKT inhibitor showing MAP2 (blue) and accumulation of βIV spectrin (red) at the AIS. White arrows indicate beginning and end of AIS ROI and the scale bar is 2 μm. B AIS fluorescence intensity signal of βIV spectrin. C Classification accuracy based on sorting signals between HC and SCZ groups for DMSO, GSK3 inhibitor, and AKT inhibitor-treated neurons. D Classification accuracy based on sorting signals between DMSO and GSK3 inhibitor-treated cells for HC and SCZ neurons, respectively. E Classification accuracy based on sorting signals between DMSO and AKT inhibitor-treated cells for HC and SCZ neurons, respectively. F Table of classification accuracy of all groups. The highest sorting accuracy was from SCZ neurons treated with AKT inhibitor.

    Article Snippet: The phosphorylation activity of β-IV spectrin peptides (PEP S-45: PAASTAAASLFECSRIK, PEP S-2543: RWGQTLPTTSSTDEGNPKR) and GSK3 peptide (H-YRRAAVPPSPSLSRHSSPHQ-pSer-EDEEE-NH2, positive control) against GSK3 kinase inhibitor CHIR99021 was evaluated using a GSK3β kinase activity assay kit (BPS Bioscience, San Diego, CA) according to the manufacturer’s protocol.

    Techniques: Fluorescence

    A Staining of MAP2 and βIV spectrin in neurons derived from HC iPSCs treated with vehicle (DMSO), GSK3 inhibitor (20 μM CHIR99021) or AKT inhibitor (50 μM triciribine). Scale bar in Ax is 20 μm. B Staining of MAP2 and βIV spectrin in neurons derived from SCZ patients with a 16p11.2 microduplication. Scale bar in Bx is 20 μm. C Effect of kinase inhibition on βIV spectrin fluorescence in neurites (n = 43 HC DMSO, 31 SCZ DMSO, 61 HC GSK3 inh., 23 SCZ GSK3 inh., 56 HC AKT inh., 24 SCZ AKT inh.). D Zoom to neurites of HC and SCZ neurons treated with vehicle, GSK3 or AKT inhibitor stained with MAP2 (blue) and accumulation of βIV spectrin (red) at the AIS. White arrows indicate beginning and end of neurite ROI and the scale bar is 5 μm. E Fluorescence intensity signal of βIV spectrin in neurites. F Classification accuracy based on sorting signals between HC and SCZ groups for DMSO, GSK3 inhibitor and AKT inhibitor-treated neurons. G Classification accuracy based on sorting signals between DMSO and GSK3 inhibitor-treated cells for HC and SCZ neurons, respectively. H Classification accuracy based on sorting signals between DMSO and AKT inhibitor-treated cells for HC and SCZ neurons, respectively. I Table of classification accuracy of all groups. # p < 0.05 by two-way mixed model ANOVA with Dunnett’s multiple comparisons test (within group effect of inhibitor vs. DMSO). *p < 0.05 and following two-way mixed model ANOVA with Sidak’s multiple comparisons test (between groups comparison of inhibitor treatment). All data are from n = 2 HC cell lines and n = 2 SCZ cell lines from patients with 16p11.2 microduplication. Each dot represents an individual cell measurement.

    Journal: Molecular Psychiatry

    Article Title: βIV spectrin abundancy, cellular distribution and sensitivity to AKT/GSK3 regulation in schizophrenia

    doi: 10.1038/s41380-025-02917-1

    Figure Lengend Snippet: A Staining of MAP2 and βIV spectrin in neurons derived from HC iPSCs treated with vehicle (DMSO), GSK3 inhibitor (20 μM CHIR99021) or AKT inhibitor (50 μM triciribine). Scale bar in Ax is 20 μm. B Staining of MAP2 and βIV spectrin in neurons derived from SCZ patients with a 16p11.2 microduplication. Scale bar in Bx is 20 μm. C Effect of kinase inhibition on βIV spectrin fluorescence in neurites (n = 43 HC DMSO, 31 SCZ DMSO, 61 HC GSK3 inh., 23 SCZ GSK3 inh., 56 HC AKT inh., 24 SCZ AKT inh.). D Zoom to neurites of HC and SCZ neurons treated with vehicle, GSK3 or AKT inhibitor stained with MAP2 (blue) and accumulation of βIV spectrin (red) at the AIS. White arrows indicate beginning and end of neurite ROI and the scale bar is 5 μm. E Fluorescence intensity signal of βIV spectrin in neurites. F Classification accuracy based on sorting signals between HC and SCZ groups for DMSO, GSK3 inhibitor and AKT inhibitor-treated neurons. G Classification accuracy based on sorting signals between DMSO and GSK3 inhibitor-treated cells for HC and SCZ neurons, respectively. H Classification accuracy based on sorting signals between DMSO and AKT inhibitor-treated cells for HC and SCZ neurons, respectively. I Table of classification accuracy of all groups. # p < 0.05 by two-way mixed model ANOVA with Dunnett’s multiple comparisons test (within group effect of inhibitor vs. DMSO). *p < 0.05 and following two-way mixed model ANOVA with Sidak’s multiple comparisons test (between groups comparison of inhibitor treatment). All data are from n = 2 HC cell lines and n = 2 SCZ cell lines from patients with 16p11.2 microduplication. Each dot represents an individual cell measurement.

    Article Snippet: The phosphorylation activity of β-IV spectrin peptides (PEP S-45: PAASTAAASLFECSRIK, PEP S-2543: RWGQTLPTTSSTDEGNPKR) and GSK3 peptide (H-YRRAAVPPSPSLSRHSSPHQ-pSer-EDEEE-NH2, positive control) against GSK3 kinase inhibitor CHIR99021 was evaluated using a GSK3β kinase activity assay kit (BPS Bioscience, San Diego, CA) according to the manufacturer’s protocol.

    Techniques: Staining, Derivative Assay, Inhibition, Fluorescence, Comparison